

ASX Release

APPENDIX 4C: THIRD QUARTER FY 2019

PERTH, AUSTRALIA – 30 April 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oromucosal drug delivery, today released its Appendix 4C for the consolidated Group for the third quarter of FY2019.

During the third quarter, the Company received income of \$331,000 in relation to its licence and feasibility study agreements. The Company's net cash outflows in operating activities for the quarter were \$670,000 which includes the second instalment of €250,000 (\$399,000) in relation to the HC Berlin Pharma settlement.

The bank balance at 31 March 2019 was \$1,707,000.

Mr Stephen Carter, SUDA's CEO, commented: "During the third quarter, SUDA continued to receive funds from its current agreements and we are now beginning to see a steadier inflow of funds from our development activities. The Company has continued its Business Development focus and looks forward to further positive announcements based on its advanced discussions with its potential partners."



Further information:
STEPHEN CARTER
CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR
SUDA Pharmaceuticals Ltd
Tel: +61 8 6142 5555
sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. SUDA has submitted a Marketing Authorisation Application to the Australian Therapeutic Goods Administration for ArTiMist®, its novel sublingual malaria treatment for children. In a Phase III trial, ArTiMist was shown to be superior to intravenous quinine. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety and cancer.

For more information, visit www.sudapharma.com

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Name of entity

Suda Pharmaceuticals Ltd

ABN

35 090 987 250

Quarter ended ("current quarter")

31 March 2019

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	331	934
1.2 Payments for		
(a) research and development	(76)	(76)
(b) product manufacturing and operating costs	-	-
(c) advertising and marketing	-	-
(d) leased assets	-	-
(e) staff costs	(265)	(822)
(f) administration and corporate costs	(267)	(1,215)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	7	24
1.5 Interest and other costs of finance paid	(1)	(164)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	745
1.8 Other (second instalment in settlement of HC Berlin Pharma matter)	(399)	(1,271)
1.9 Net cash from / (used in) operating activities	(670)	(1,845)

2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) property, plant and equipment	(45)	(294)
(b) businesses (see item 10)	-	-

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
(c) investments	-	-
(d) intellectual property	(327)	(840)
(e) other non-current assets	-	-
2.2 Proceeds from disposal of:		
(a) property, plant and equipment	-	-
(b) businesses (see item 10)	-	-
(c) investments	-	-
(d) intellectual property	-	-
(e) other non-current assets	-	-
2.3 Cash flows from loans to other entities	-	-
2.4 Dividends received (see note 3)	-	-
2.5 Other (provide details if material)	-	-
2.6 Net cash from / (used in) investing activities	(372)	(1,134)

3. Cash flows from financing activities		
3.1 Proceeds from issues of shares	-	6,789
3.2 Proceeds from issue of convertible notes	-	
3.3 Proceeds from exercise of share options	-	-
3.4 Transaction costs related to issues of shares, convertible notes or options	-	(199)
3.5 Proceeds from borrowings	-	140
3.6 Repayment of borrowings	-	(2,142)
3.7 Transaction costs related to loans and borrowings	-	-
3.8 Dividends paid	-	-
3.9 Other (provide details if material)	-	-
3.10 Net cash from / (used in) financing activities	-	4,588

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of quarter/year to date	2,749	98
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(670)	(1,845)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(372)	(1,134)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	-	4,588
4.5	Effect of movement in exchange rates on cash held	-	-
4.6	Cash and cash equivalents at end of quarter	1,707	1,707

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	807	1,349
5.2	Call deposits	900	1,400
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	1,707	2,749

6. Payments to directors of the entity and their associates

6.1 Aggregate amount of payments to these parties included in item 1.2

6.2 Aggregate amount of cash flow from loans to these parties included in item 2.3

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

**Current quarter
\$A'000**

177

-

Salaries, consulting fees and directors' fees paid for the current quarter.

Appendix 4C
Quarterly report for entities subject to Listing Rule 4.7B

7. Payments to related entities of the entity and their associates	Current quarter \$A'000
7.1 Aggregate amount of payments to these parties included in item 1.2	-
7.2 Aggregate amount of cash flow from loans to these parties included in item 2.3	-
7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2	

--

8. Financing facilities available <i>Add notes as necessary for an understanding of the position</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
8.1 Loan facilities	-	-
8.2 Credit standby arrangements	-	-
8.3 Other (Convertible Notes)	-	-
8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.		

--

9. Estimated cash outflows for next quarter	\$A'000
9.1 Research and development	(82)
9.2 Product manufacturing and operating costs	-
9.3 Advertising and marketing	-
9.4 Leased assets	-
9.5 Staff costs	(270)
9.6 Administration and corporate costs	(380)
9.7 Other (provide details if material)	-
9.8 Total estimated cash outflows	(732)

10. Acquisitions and disposals of business entities (items 2.1(b) and 2.2(b) above)	Acquisitions	Disposals
10.1 Name of entity		
10.2 Place of incorporation or registration		
10.3 Consideration for acquisition or disposal		
10.4 Total net assets		
10.5 Nature of business		

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.



Sign here:
(Director/Company secretary)

Date: 30 April 2019.....

Print name:Stephen Carter.....

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.
2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.